Abstract: The present invention relates to in vitro methods of assessing the susceptibility or responsiveness of a subject to the treatment with an epidermal growth factor receptor (EGFR) inhibitor/antagonist, wherein the subject has been diagnosed or suspected of suffering from inflammation-associated cancer. These methods comprise determining the level of expression of EGFR in myeloid cells in a sample from the subject, wherein an expression of EGFR in the myeloid cells is indicative of the subject being susceptible to the treatment with an EGFR inhibitor/antagonist.

Abstract: The present invention relates to heteroaromatic chalcone derivatives, particularly the compounds of formula (I) as described and defined herein, pharmaceutical compositions comprising these compounds, and their medical use, including their use in the treatment or prevention of cancer and, in particular, in the treatment or prevention of hematologic malignancies.

Abstract: The present invention relates to a method for Magnetic Resonance Imaging to depict an object by an image having pixels representing volume element of the object. The method comprises: Immobilizing the object and acquiring a reference image at a first echo time immediately following an excitation, wherein said reference image is complex-valued, with a reference magnitude value and a reference phase value for each pixel; acquiring a target image of the object with said receiver coil at a pre-selected second echo time, wherein said target image is complex-valued, with a target magnitude value and a target phase value for each pixel; subtracting, pixel by pixel, the reference phase value from the target phase value to obtain a corrected phase value for each pixel; and obtaining said image from said target magnitude values and said corrected phase values.

Abstract: The present invention relates to a cell culture model of vascular calcification, comprising a first type of cultured vascular smooth muscle cells and a second type of cultured vascular smooth muscle cells, wherein the first type and the second type of vascular smooth muscle cells originate from blood vessels having a different diameter, e.g., from the human aorta and from a human coronary artery, respectively. This model allows to generate and analyze vascular calcification processes, including early calcification processes, in an advantageously simple and cost-effective way and with high sensitivity. It can further be used to identify and examine compounds capable of halting, inhibiting or reversing such vascular calcification processes.

Abstract: The present invention relates to a pharmaceutical composition comprising complement split product C4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The C4d to be used may be a multimer. Accordingly, also C4d multimers and their use in medicine, like the treatment of inflammatory conditions, is provided. Furthermore, the present invention provides a protein complex comprising C4d interacting with its ILT4 receptor. This protein complex may be used in screening methods Also antibodies specifically binding to the C4d multimer or the C4d/ILT4-protein complex are subject of the present invention.

Abstract: The present invention relates to a pharmaceutical composition comprising complement split product C4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The C4d to be used may be a multimer. Accordingly, also C4d multimers and their use in medicine, like the treatment of inflammatory conditions, is provided. Furthermore, the present invention provides a protein complex comprising C4d interacting with its ILT4 receptor. This protein complex may be used in screening methods Also antibodies specifically binding to the C4d multimer or the C4d/ILT4-protein complex are subject of the present invention.

Abstract: Provided are methods for suppressing IgE and IgG-mediated allergic reactions through monoclonal antibody applications. More specifically, methods are herein provided for safe induction of rapid desensitization. Specific embodiments are herein provided for suppressing allergic reactions in a subject, including specific methods of providing a monoclonal antibody selected from the group consisting of anti-Fc?RIa and anti-Fc?RIIb / RIII; administering the antibody to a subject at a dose that is lower than the level required to induce shock; and administering sequentially escalating doses of the monoclonal antibody so as to induce rapid desensitization to an allergen, thereby suppressing allergic reaction in the subject.

Abstract: The present invention relates to a method for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma, wherein said method comprises determining the amount of soluble AXL in a sample from the patient. The patient is assessed to suffer from cancer or to be prone to suffering from cancer when the amount of soluble AXL is increased in comparison to a control. The present invention relates to the use of soluble AXL for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma. Also a kit for use in the methods of the present invention is provided.

Abstract: The present invention belongs to the field of biotechnology. More specifically, the invention relates to chimeric fusion proteins comprising a light activated protein domain, e.g., a newly characterized light-oxygen-voltage-sensing (LOV) domain or a light sensing domain of the cyanobacterial phytochrome (PHY) CPH1, wherein the chimeric fusion protein is capable of dimerizing upon excitation with light of a suitable wavelength. Said fusion proteins further comprise the intracellular part of a receptor tyrosine kinase (RTK). The invention further relates to nucleic acid molecules encoding said chimeric fusion proteins; non-human transgenic animals expressing the chimeric fusion protein encoded by said nucleic acid molecules; as well as uses of said chimeric fusion proteins, e.g. in a screening method.

Abstract: The invention discloses the use of glutathione S-transferase Pb (GSTP1) for the prevention or treatment of cardiomyopathies or ischemic heart diseases and for the diagnosis thereof.

Abstract: The invention relates to a bone screw set for fixing two bone fragments, especially for treating a scaphoid bone fracture or a scaphoid bone pseudoarthrosis, comprising a first bone screw (1) and at least one second bone screw (2). The first bone screw (1) is preferably embodied as a compression screw, and the first and second bone screws (1, 2) comprise interacting engagement means for fixing the second bone screw (2) in a position, in relation to the first bone screw (1), wherein at least part of the second bone screw protrudes from the cross-section of the first bone screw (1).

Abstract: A method of inducing differentiation of mammalian cells into cardiomyocyte-like cells by contacting the mammalian cell with a triazine compound of formula (I), wherein X is independently —NR4— or —O—, R4 is hydrogen or C1-6-alkyl; R1 is hydroxy, C1-6-alkyl, C1-6-alkoxy, carboxy, C1-6-alkoxycarbonyl, halo, cyano, nitro, formyl, amino, C1-6-alkylamino, or di-C1-6-alkylamino, the C1-6-alkyl or -alkoxy residue being optionally substituted with one or more R5 substituents selected from hydroxy, halo, cyano, and nitro; n is 0 to 5; R2 is hydrogen, aryl, heteroaryl, or C1-6-alkyl, the aryl or heteroaryl residue being optionally substituted with one or more R1 substituents, and where the C1-6-alkyl is optionally further substituted with one or more R5 substituents; and R3 is selected from hydrogen, halo, NR4R7, OR7, SR7, and R7, where the same options apply for R7 as for R2; with the proviso that the compound of formula (I) is not 3-[(4,6-diphenoxy-1,3,5-triazin-2-yl)amino]benzoic acid.

Abstract: The invention discloses the use of glutathione S-transferase P1 (GSTP1) for the prevention or treatment of cardiomyopathies or ischemic heart diseases and for the diagnosis thereof.

Abstract: The invention relates to a method and a device for processing 3-D image date of a skull (S), wherein image date are selected or calculated for the 3-D image data and are presented as 2-D image data in a plane. For fast, overview-like inspection of the skull (S), the skull surface (O) is determined from the 3-D image data, and the corresponding image data at a defined distance (d) from the skull surface (O) are determined and presented as 2-D image data in a plane.

Abstract: Provided is a compound of formula (I), and/or salt thereof, wherein the radicals have various meanings, a process for producing cardiomyocyte-like cells from mammalian cells by culturing mammalian cells in the presence of the compound of formula (I), the pharmaceutical use of compounds of formula (I) for producing cardiomyocyte-like cells from omnipotent, pluripotent, or lineage committed mammalian cells, and the use of thus produced cardiomyocyte-like cells for treating disorders associated with impaired function of the heart.

Abstract: The invention refers to PDGFRbeta inhibitor for use in the antiproliferative treatment of T-cell lymphoma, in particular NHL, ALCL and PTCL.

Abstract: The invention relates to a device for the punctual stimulation of the nerve endings located in the region of the ears, said device having a battery-powered therapeutic current generator (3) arranged in a housing (4) which is to be worn in the region of the ear, and said generator supplying a low frequency therapeutic current. The therapeutic current generator (3) has a plurality of output channels (9a, 9b, 9c), wherein each output channel is associated with its own stimulation electrode (6a, 6b, 6c), and these output channels are connected to a micro-computer circuit (10) on the input side. Each output channel (9a, 9b, 9c) contains an amplifier (15a, 15b, 15c), controlled by a digital-analogue converter (12) and designed for bipolar output signals.

Abstract: The invention discloses the use of glutathione S-transferase P1 (GSTP1) for the prevention or treatment of cardiomyopathies or ischemic heart diseases and for the diagnosis thereof.

Abstract: The invention relates to a method and a device for processing 3-D image date of a skull (S), wherein image date are selected or calculated for the 3-D image data and are presented as 2-D image data in a plane. For fast, overview-like inspection of the skull (S), the skull surface (O) is determined from the 3-D image data, and the corresponding image data at a defined distance (d) from the skull surface (O) are determined and presented as 2-D image data in a plane.

Abstract: Method for diagnosing a cardiovascular disease in an individual comprising the steps of: providing a sample of an individual; determining the amount of cytokeratin-18 (CK-18) or fragments thereof and/or interleukin-1? precursor (IL-1? precursor) in the sample; comparing the amount of CK-18 or fragments thereof and/or IL-1? precursor in the sample to the amount of CK-18 or fragments thereof and/or IL-1? precursor present in a reference control of at least one individual not suffering from a cardiovascular disease; and diagnosing a cardiovascular disease if the amount of CK-18 or fragments thereof in the sample is increased in comparison to the amount of CK-18 or fragments thereof in the reference control and/or the amount of IL-1? precursor in the sample is decreased in comparison to the amount of IL-1? precursor in the reference control.